News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CMS (00867.HK) New Drug MG-K10 Marketing Application Accepted
CMS (00867.HK) announced that the marketing authorization application in China for the Category 1 innovative drug anti-IL-4R?humanized monoclonal antibody injection MG-K10 (generic...
Reset
Send
The window will close in 5 seconds
CMS (00867.HK) New Drug MG-K10 Marketing Application Accepted
Close
Recommend
2
Positive
2
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CMS (00867.HK)  +0.010 (+0.091%)    Short selling $4.97M; Ratio 14.810%   announced that the marketing authorization application in China for the Category 1 innovative drug anti-IL-4R?humanized monoclonal antibody injection MG-K10 (generic name: Kemeiqi Bai Monoclonal Antibody Injection), for the indication of seasonal allergic rhinitis, has been accepted by the National Medical Products Administration of China. The Group holds co-development rights and exclusive commercialization rights for the product. The drug is intended for adult patients with moderate-to-severe seasonal allergic rhinitis who have inadequate symptom control after treatment with intranasal corticosteroids. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.